Associated Papers
A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.
Oh HC et al.
Genome Biology, 2026
Germline duplication of MYCN predisposes to childhood embryonal tumours.
Taylor CA et al.
Ebiomedicine, 2026
Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders.
Ma Y et al.
Cell Reports, 2026
Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies.
Kang W et al.
Communications Medicine, 2026
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Ai X et al.
European Journal of Cancer (oxford, England : 1990), 2026
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study.
Saint-Charles A et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Precision Oncology for Pediatric Solid Tumors Using In-Hospital Pediatric/AYA Malignancy-Specific Panel Sequencing.
Kojima M et al.
Cancer Science, 2025
ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer.
Machlah YM et al.
Thyroid : Official Journal of the American Thyroid Association, 2025
Resource: A compendium of HLA types and expression in pediatric cancer models.
Guan Y et al.
Iscience, 2025
Therapeutic potential of lorlatinib in ALK-mutated metastatic paraganglioma: Insights from clinical case report and literature review.
Nigro MC et al.
Critical Reviews in Oncology/hematology, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of an ALK degrader for lorlatinib-resistant compound mutations.
Gao F et al.
European Journal of Medicinal Chemistry, 2025
Integrative machine learning predicts activating kinase mutations for precision oncology.
Wang Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Scollon S et al.
Jco Precision Oncology, 2025
Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA.
Danilenko M et al.
International Journal of Molecular Sciences, 2025
Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.
Matkar S et al.
Molecular Cancer Therapeutics, 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131.
Zhao F et al.
International Journal of Biological Macromolecules, 2025
Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study.
Sakaguchi H et al.
Esmo Open, 2025
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers.
Guerra AD et al.
Nature Communications, 2025
Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.
Farouk Sait S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Massively parallel immunopeptidome by DNA sequencing provides insights into cancer antigen presentation.
Shi Q et al.
Nature Genetics, 2025
Large-scale RNA-Seq mining reveals ciclopirox olamine induces TDP-43 cryptic exons.
Sinha IR et al.
Nature Communications, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Functional assays in Drosophila facilitate classification of variants of uncertain significance associated with rare diseases.
Mok JW et al.
Genome Research, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.
Waliany S et al.
Clinical Lung Cancer, 2025
Iruplinalkib for G1202R-mutant non-small cell lung cancer with anaplastic lymphoma kinase double fusion failed to alectinib: a case report.
Yang G et al.
Anti-cancer Drugs, 2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.
Berko ER et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2025
Genetic variants of m1A modification genes and the risk of neuroblastoma: novel insights from a Chinese case-control study.
Chang J et al.
Human Genomics, 2025
Anaplastic lymphoma kinase enhances Wnt signaling through R-spondin: A new dimension to ALK-mediated oncogenesis.
Sandhu K et al.
International Journal of Biological Macromolecules, 2025
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations.
He P et al.
European Journal of Medicinal Chemistry, 2025
Amino Acid Metabolism Subtypes in Neuroblastoma Identifying Distinct Prognosis and Therapeutic Vulnerabilities.
Zhou X et al.
Journal of Proteome Research, 2025
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.
Elmenawi S et al.
Current Oncology Reports, 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Multiplexed in vivo base editing identifies functional gene-variant-context interactions.
Acosta J et al.
Biorxiv : the Preprint Server for Biology, 2025
Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma.
Hollander JF et al.
Cancer Research Communications, 2025
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer.
Zapata Dongo RJ et al.
Frontiers in Pharmacology, 2025
Novel ALK gene mutation in inflammatory myofibroblastic tumor of the thyroid: a case report.
Guangxu Y et al.
Frontiers in Oncology, 2025
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ et al.
Cancer Discovery, 2024
In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALKL1196M/G1202R mutation.
Zhang X et al.
Computers in Biology and Medicine, 2024